Terms: = Germ cell tumor AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246
276 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
3. SOMATIC DEFICIENT MISMATCH REPAIR ASSESSED BY IMMUNOHISTOCHEMISTRY AND CLINICAL FEATURES IN BRAZILIAN GLIOBLASTOMA PATIENTS.
Yamada CAF; Malheiros SMF; Do Amaral LLF; Lancellotti CLP
Exp Oncol; 2023 Dec; 45(3):297-311. PubMed ID: 38186025
[TBL] [Abstract] [Full Text] [Related]
4. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
5. Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G; Szőke P; Bátai B; Nagy T; Papp G; Kránitz N; Rajnai H; Reiniger L; Bödör C; Scheich B
Sci Rep; 2023 Oct; 13(1):18436. PubMed ID: 37891325
[TBL] [Abstract] [Full Text] [Related]
6. Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study.
Kaneko M; Nakashima M; Sugiura K; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Osawa S; Tatsuta K; Kurachi K; Baba S; Iwashita Y; Arai T; Sugimura H; Maekawa M; Sugimoto K; Iwaizumi M
Medicine (Baltimore); 2023 Sep; 102(38):e35022. PubMed ID: 37746995
[TBL] [Abstract] [Full Text] [Related]
7. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
[TBL] [Abstract] [Full Text] [Related]
8. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract] [Full Text] [Related]
9. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
[TBL] [Abstract] [Full Text] [Related]
10. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
11. Mixed adenoneuroendocrine carcinoma of the gallbladder.
Wang Q; Li L; Li J; Fan W
Rev Esp Enferm Dig; 2024 Jan; 116(1):48-49. PubMed ID: 37073699
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive profiling of pathogenic germline large genomic rearrangements in a pan-cancer analysis.
Sun Z; Bai C; Su M; Tang H; Wu X; Wang Y; Bao H; Liu X; Wu X; Shao Y; Xu B
Mol Oncol; 2023 Sep; 17(9):1917-1929. PubMed ID: 37013911
[TBL] [Abstract] [Full Text] [Related]
13. Renal cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
[TBL] [Abstract] [Full Text] [Related]
14. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
[TBL] [Abstract] [Full Text] [Related]
15. Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
Wu J; Jin S; Gu C; Wei Y; Zhu Y; Necchi A; Shariat SF; Pan J; Gan H; Dai B; Zhang H; Shi G; Zhu Y; Shen Y; Zhu Y; Ye D
Cell Rep Med; 2023 Jan; 4(1):100883. PubMed ID: 36630951
[TBL] [Abstract] [Full Text] [Related]
16. Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline msh2 mutation.
Xu Y; Li Q; Zhao J; Ni X; Li P; Hu W
Front Immunol; 2022; 13():1064488. PubMed ID: 36518767
[TBL] [Abstract] [Full Text] [Related]
17. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
[TBL] [Abstract] [Full Text] [Related]
18. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
Li K; Liu Y; Han J; Gui J; Zhang X
Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
[TBL] [Abstract] [Full Text] [Related]
19. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
[TBL] [Abstract] [Full Text] [Related]
20. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract] [Full Text] [Related]
[Next]